RESEARCH ARTICLE | DOI: https://doi.org/PP-IHM-RA-0005
1 Department of Biomedical Sciences, New Horizons Medical University, Boston, USA
2 Department of Microbiology, Institute of Clinical Research, New Delhi, India
3 Clinical Trials Unit, King Faisal Hospital, Riyadh, Saudi Arabia
*Corresponding Author: Jane L. Thomson, Department of Biomedical Sciences, New Horizons Medical University, Boston, USA
Citation: Jane L. Thomson, Rajeev Menon, Aisha K. Omar (2025), Evaluating the Efficacy of a Novel Antimicrobial Peptide in the Treatment of Multidrug-Resistant Infections J Innovations in Healthcare and Medicine 1(1): dx.doi.org/IHM/PP.0005
Copyright 
:
© 2025 Jane L. Thomson. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 28 June 2025 | Accepted: 01 July 2025 | Published: 12 July 2025
Keywords: antimicrobial peptide, multidrug resistance, e. coli, k. pneumoniae, peptide therapy, clinical microbiology, amp-x37
The rise in multidrug-resistant (MDR) bacterial infections poses a global health threat, requiring innovative therapeutic strategies beyond traditional antibiotics. This study investigates the in vitro and in vivo efficacy of a novel antimicrobial peptide, AMP-X37, against MDR strains of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus. AMP-X37 was synthesized and tested for minimum inhibitory concentration (MIC), bactericidal activity, and safety in a murine sepsis model. Results demonstrated that AMP-X37 exhibited potent antibacterial activity at low MIC levels and significantly reduced bacterial load in vivo without notable toxicity. These findings suggest that AMP-X37 may represent a promising therapeutic candidate in combating MDR bacterial infections.
Antibiotic resistance continues to compromise the efficacy of first-line and even last-resort antibiotics, with MDR bacterial infections leading to increased morbidity, mortality, and healthcare costs. The World Health Organization has identified the need for novel therapeutic agents as a global priority. Antimicrobial peptides (AMPs) offer a potential solution due to their broad-spectrum activity, rapid bactericidal effects, and reduced likelihood of resistance development. AMP-X37 is a synthetic peptide designed to mimic natural host-defense peptides while enhancing stability and specificity. This study aims to evaluate the antimicrobial properties of AMP-X37 against key MDR pathogens and to assess its therapeutic potential in a preclinical animal model.
Peptide Synthesis and Characterization
AMP-X37 was synthesized using solid-phase peptide synthesis with standard Fmoc chemistry. Purification was conducted using high-performance liquid chromatography, and structural confirmation was achieved through mass spectrometry.
Bacterial Strains and Culture Conditions
Clinical MDR isolates of E. coli, K. pneumoniae, and S. aureus were obtained from hospital repositories and verified using standard microbiological and molecular techniques. Cultures were maintained in Mueller-Hinton broth under aerobic conditions.
Minimum Inhibitory Concentration (MIC) Assay
The MIC values of AMP-X37 were determined using broth microdilution according to CLSI guidelines. Controls included standard antibiotics such as ciprofloxacin and vancomycin.
Bactericidal Activity Assay
Time-kill curves were plotted by sampling bacterial suspensions at 0, 2, 4, 8, and 24 hours post-treatment with AMP-X37 at 1x and 2x MIC concentrations.
Murine Sepsis Model
BALB/c mice were injected intraperitoneally with lethal doses of MDR E. coli. Treatment groups received AMP-X37 intravenously 1 hour post-infection. Control groups received saline or ciprofloxacin. Bacterial load in blood and organs was assessed after 48 hours.
Statistical Analysis
Data were analyzed using ANOVA and Student’s t-test. A p-value <0>
AMP-X37 demonstrated strong antimicrobial activity, with MICs ranging from 0.5 to 2 µg/mL against all tested strains. Time-kill studies showed complete eradication of bacteria within 8 hours at 2x MIC. In the murine sepsis model, AMP-X37 treatment led to a >90% reduction in bacterial load in the blood and liver compared to untreated controls (p < 0>
The study provides strong evidence supporting AMP-X37 as a potent therapeutic candidate against MDR infections. Unlike traditional antibiotics that target specific bacterial pathways, AMP-X37 disrupts bacterial membranes, reducing the likelihood of resistance development. Its effectiveness in the murine sepsis model further validates its potential clinical application. However, further studies are needed to assess pharmacokinetics, long-term safety, and efficacy in human trials. This study contributes to the growing field of peptide therapeutics, which may revolutionize the treatment of resistant infections.
AMP-X37 exhibits significant in vitro and in vivo activity against multidrug-resistant bacteria and may represent a viable alternative to conventional antibiotics. The absence of toxicity and its ability to significantly reduce bacterial burden in an animal model suggest its promise as a next-generation antimicrobial agent. Further clinical development is warranted.
